Celecoxib and ion channels: A story of unexpected discoveries

European Journal of Pharmacology

Volumn 730, Issue 1, 2014, Pages 61-71

  Frolov, Roman V ^a   Singh, Satpal ^b  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Calcium channel; Celecoxib; COX 2 inhibitor; Potassium channel; Sodium channel

Indexed keywords

CALCIUM CHANNEL L TYPE; CELECOXIB; CYCLOOXYGENASE 2; ION CHANNEL; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KV1.5; SHAB POTASSIUM CHANNEL; SHAL POTASSIUM CHANNEL; SODIUM CHANNEL NAV1.6; SODIUM CHANNEL NAV1.7; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ACTION POTENTIAL; ANALGESIC ACTIVITY; BINDING SITE; CARDIOVASCULAR EFFECT; CHANNEL GATING; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HEART MUSCLE CELL; HEART RATE; HUMAN; IC 50; MEMBRANE POTENTIAL; NERVE CELL; NERVE CELL EXCITABILITY; NONHUMAN; PAIN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SPINAL GANGLION; VASODILATATION; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM;

ANIMALS; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; ION CHANNELS; PYRAZOLES; SULFONAMIDES;

EID: 84896415877     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.02.032     Document Type: Review

References (89)

1. Amin, A.S., Tan, H.L., Wilde, A.A., 2010. Cardiac ion channels in health and disease. Heart Rhythm 7, 117.
2. Arias II, O., Carrillo, E., Meza-Torres, B., Barriga-Montoya, C., Balleza, D., Gomez-Lagunas, F., 2011. Induction of a fast inactivation gating on delayed rectifier Shab K(+) channels by the anti-inflammatory drug celecoxib. Channels (Austin) 5, 56.
3. Balderas, E., Sanchez-Cardenas, C., Chavez, J.C., de la Vega Beltran, J.L., Gomez-Lagunas, F., Trevino, C.L., Darszon, A., 2013. The anti-inflammatory drug celecoxib inhibits t-type Ca currents in spermatogenic cells yet it elicits the acrosome reaction in mature sperm. FEBS Lett.
4. Baranauskas, G., Tkatch, T., Surmeier, D.J., 1999. Delayed rectifier currents in rat globus pallidus neurons are attributable to Kv2.1 and Kv3.1/3.2 K(+) channels. J. Neurosci. 19, 6394.
5. Barry, D.M., Trimmer, J.S., Merlie, J.P., Nerbonne, J.M., 1995. Differential expression of voltage-gated K+ channel subunits in adult rat heart. Relation to functional K+ channels? Circ. Res. 77, 361.
6. Bellocq, C., van Ginneken, A.C., Bezzina, C.R., Alders, M., Escande, D., Mannens, M. M., Baro, I., Wilde, A.A., 2004. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 109, 2394.
7. Benveniste, M., Mayer, M.L., 1995. Trapping of glutamate and glycine during open channel block of rat hippocampal neuron NMDA receptors by 9-aminoacridine. J. Physiol. 483, 367 (Pt 2).
8. Bondarenko, V.E., Szigeti, G.P., Bett, G.C., Kim, S.J., Rasmusson, R.L., 2004. Computer model of action potential of mouse ventricular myocytes. Am. J. Physiol. Heart. Circ. Physiol. 287, H1378.
9. Brueggemann, L.I., Mackie, A.R., Mani, B.K., Cribbs, L.L., Byron, K.L., 2009. Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. Mol. Pharmacol. 76, 1053.
10. Brugada, P., Brugada, J., 1992. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J. Am. Coll. Cardiol. 20, 1391.
11. Brugada, R., Hong, K., Dumaine, R., Cordeiro, J., Gaita, F., Borggrefe, M., Menendez, T. M., Brugada, J., Pollevick, G.D., Wolpert, C., Burashnikov, E., Matsuo, K., Wu, Y.S., Guerchicoff, A., Bianchi, F., Giustetto, C., Schimpf, R., Brugada, P., Antzelevitch, C., 2004. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 109, 30.
12. Burnier, M., 2005. The safety of rofecoxib. Expert Opin. Drug Saf. 4, 491.
13. Cervello, M., D. Bachvarov, A. Cusimano, F. Sardina, A. Azzolina, N. Lampiasi, L. Giannitrapani, J.A. McCubrey, G. Montalto, 2011, COX-2-Dependent and COX-2-Independent Mode of Action of Celecoxib in Human Liver Cancer Cells, OMICS.
14. Chandy, K.G., DeCoursey, T.E., Cahalan, M.D., McLaughlin, C., Gupta, S., 1984. Voltage-gated potassium channels are required for human T lymphocyte activation. J. Exp. Med. 160, 369.
15. Chen, Y.H., Xu, S.J., Bendahhou, S., Wang, X.L., Wang, Y., Xu, W.Y., Jin, H.W., Sun, H., Su, X.Y., Zhuang, Q.N., Yang, Y.Q., Li, Y.B., Liu, Y., Xu, H.J., Li, X.F., Ma, N., Mou, C.P., Chen, Z., Barhanin, J., Huang, W., 2003. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 299, 251.
16. Ching, T.T., Chiang, W.C., Chen, C.S., Hsu, A.L., 2011. Celecoxib extends C. elegans lifespan via inhibition of insulin-like signaling but not cyclooxygenase-2 activity. Aging Cell 10, 506.
17. Chiu, H.C., Yang, J., Soni, S., Kulp, S.K., Gunn, J.S., Schlesinger, L.S., Chen, C.S., 2009. Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis. Antimicrob. Agents Chemother. 53, 2998.
18. Christophersen, I.E., Olesen, M.S., Liang, B., Andersen, M.N., Larsen, A.P., Nielsen, J.B., Haunso, S., Olesen, S.P., Tveit, A., Svendsen, J.H., Schmitt, N., 2013. Genetic variation in KCNA5: impact on the atrial-specific potassium current IKur in patients with lone atrial fibrillation. Eur. Heart J. 34, 1517.
19. Curran, M.E., Splawski, I., Timothy, K.W., Vincent, G.M., Green, E.D., Keating, M.T., 1995. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80, 795.
20. Davies, N.M., McLachlan, A.J., Day, R.O., Williams, K.M., 2000. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin. Pharmacokinet. 38, 225.
21. Delisle, B.P., Anson, B.D., Rajamani, S., January, C.T., 2004. Biology of cardiac arrhythmias: ion channel protein trafficking. Circ. Res. 94, 1418.
22. Dogne, J.M., Thiry, A., Pratico, D., Masereel, B., Supuran, C.T., 2007. Dual carbonic anhydrase - cyclooxygenase-2 inhibitors. Curr. Top. Med. Chem. 7, 885.
23. Du, X., Zhang, X., Qi, J., An, H., Li, J., Wan, Y., Fu, Y., Gao, H., Gao, Z., Zhan, Y., Zhang, H., 2011. Characteristics and molecular basis of celecoxib modulation on Kv7 potassium channels. Br. J. Pharmacol., 1722-1737
24. FDA, US Food and Drug Administration. Propoxyphene: Withdrawal - Risk of Cardiac Toxicity, 2010.
25. Franco, R., DeHaven, W.I., Sifre, M.I., Bortner, C.D., Cidlowski, J.A., 2008. Glutathione depletion and disruption of intracellular ionic homeostasis regulate lymphoid cell apoptosis. J. Biol. Chem. 283, 36071.
26. Frolov, R.V., Berim, I.G., Singh, S., 2008a. Inhibition of delayed rectifier potassium channels and induction of arrhythmia: a novel effect of celecoxib and the mechanism underlying it. J. Biol. Chem. 283, 1518.
27. Frolov, R.V., Bondarenko, V.E., Singh, S., 2010a. Mechanisms of Kv2.1 channel inhibition by celecoxib - modification of gating and channel block. Br. J. Pharmacol. 159, 405.
28. Frolov, R.V., Ignatova, II, Singh, S., 2010b. Mechanism of K(v)2.1 channel inhibition by a selective COX-2 inhibitor SC-791-modification of gating. Brain Res. 1359, 67.
29. Frolov, R.V., Ignatova, II, Singh, S., 2011. Inhibition of HERG potassium channels by celecoxib and its mechanism. PLoS One 6, e26344.
30. Frolov, R.V., Singh, S., 2012. Inhibition of ion channels and heart beat in Drosophila by selective COX-2 inhibitor SC-791. PLoS One 7, e38759.
31. Frolov, R.V., M.M. Slaughter, S. Singh, 2008b, Effects of celecoxib on ionic currents and spontaneous firing in rat retinal neurons, Neuroscience.
32. Gaborit, N., Le Bouter, S., Szuts, V., Varro, A., Escande, D., Nattel, S., Demolombe, S., 2007. Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J. Physiol. 582, 675.
33. Gaborit, N., Wichter, T., Varro, A., Szuts, V., Lamirault, G., Eckardt, L., Paul, M., Breithardt, G., Schulze-Bahr, E., Escande, D., Nattel, S., Demolombe, S., 2009. Transcriptional profiling of ion channel genes in Brugada syndrome and other right ventricular arrhythmogenic diseases. Eur. Heart J. 30, 487.
34. Gonzalez, T., Navarro-Polanco, R., Arias, C., Caballero, R., Moreno, I., Delpon, E., Tamargo, J., Tamkun, M.M., Valenzuela, C., 2002. Assembly with the Kvbeta1.3 subunit modulates drug block of hKv1.5 channels. Mol. Pharmacol. 62, 1456.
35. Grosch, S., Maier, T.J., Schiffmann, S., Geisslinger, G., 2006. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst. 98, 736.
36. Gwanyanya, A., Macianskiene, R., Mubagwa, K., 2012. Insights into the effects of diclofenac and other non-steroidal anti-inflammatory agents on ion channels. J. Pharm. Pharmacol. 64, 1359.
37. Hancox, J.C., McPate, M.J., El Harchi, A., Zhang, Y.H., 2008. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol. Ther. 119, 118.
38. Hasinoff, B.B., Patel, D., Wu, X., 2007. The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independent. Cardiovasc. Toxicol. 7, 19.
39. Jehle, J., Schweizer, P.A., Katus, H.A., Thomas, D., 2011. Novel roles for hERG K(+) channels in cell proliferation and apoptosis. Cell. Death Dis. 2, e193.
40. Kalgutkar, A.S., Crews, B.C., Rowlinson, S.W., Garner, C., Seibert, K., Marnett, L.J., 1998. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 280, 1268.
41. Liu, H., Clancy, C., Cormier, J., Kass, R., 2003. Mutations in cardiac sodium channels: clinical implications. Am. J. Pharmacogen. 3, 173.
42. Lupoglazoff, J.M., Denjoy, I., Villain, E., Fressart, V., Simon, F., Bozio, A., Berthet, M., Benammar, N., Hainque, B., Guicheney, P., 2004. Long QT syndrome in neonates: conduction disorders associated with HERG mutations and sinus bradycardia with KCNQ1 mutations. J. Am. Coll. Cardiol. 43, 826.
43. Ma, K., Zhou, Q.H., Chen, J., Du, D.P., Ji, Y., Jiang, W., 2008. TTX-R Na+ current-reduction by celecoxib correlates with changes in PGE(2) and CGRP within rat DRG neurons during acute incisional pain. Brain Res. 1209, 57.
44. Macias, A., Moreno, C., Moral-Sanz, J., Cogolludo, A., David, M., Alemanni, M., Perez-Vizcaino, F., Zaza, A., Valenzuela, C., Gonzalez, T., 2010. Celecoxib blocks cardiac Kv1.5, Kv4.3 and Kv7.1 (KCNQ1) channels: effects on cardiac action potentials. J. Mol. Cell. Cardiol. 49, 984.
45. Malin, S.A., Nerbonne, J.M., 2002. Delayed rectifier K+ currents, IK, are encoded by Kv2 alpha-subunits and regulate tonic firing in mammalian sympathetic neurons. J. Neurosci. 22, 10094.
46. Martin, C.A., Huang, C.L., Matthews, G.D., 2013. The role of ion channelopathies in sudden cardiac death: implications for clinical practice. Ann. Med. 45, 364.
47. Mi, Y., Zhang, X., Zhang, F., Qi, J., Gao, H., Huang, D., Li, L., Zhang, H., Du, X., 2013. The role of potassium channel activation in celecoxib-induced analgesic action. PLoS One 8, e54797.
48. Misonou, H., Mohapatra, D.P., Park, E.W., Leung, V., Zhen, D., Misonou, K., Anderson, A.E., Trimmer, J.S., 2004. Regulation of ion channel localization and phosphorylation by neuronal activity. Nat. Neurosci. 7, 711.
49. Misonou, H., Mohapatra, D.P., Trimmer, J.S., 2005. Kv2.1: a voltage-gated k+ channel critical to dynamic control of neuronal excitability. Neurotoxicology 26, 743.
50. Murakoshi, H., Trimmer, J.S., 1999. Identification of the Kv2.1 K+ channel as a major component of the delayed rectifier K+ current in rat hippocampal neurons. J. Neurosci. 19, 1728.
51. O'Hara, T., Y. Rudy, 2011, Quantitative comparison of cardiac ventricular myocyte electrophysiology and response to drugs in human and non-human species, Am. J. Physiol. Heart. Circ. Physiol, H1023-H1030.
52. Olson, T.M., Alekseev, A.E., Liu, X.K., Park, S., Zingman, L.V., Bienengraeber, M., Sattiraju, S., Ballew, J.D., Jahangir, A., Terzic, A., 2006. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum. Mol. Gen. 15, 2185.
53. Ordog, B., Brutyo, E., Puskas, L.G., Papp, J.G., Varro, A., Szabad, J., Boldogkoi, Z., 2006. Gene expression profiling of human cardiac potassium and sodium channels. Int. J. Cardiol. 111, 386.
54. Park, S.Y., Kim, T.H., Kim, H.I., Shin, Y.K., Lee, C.S., Park, M., Song, J.H., 2007. Celecoxib inhibits Na+ currents in rat dorsal root ganglion neurons. Brain Res. 1148, 53.
55. Patel, A.J., Lazdunski, M., Honore, E., 1997. Kv2.1/Kv9.3, a novel ATP-dependent delayed-rectifier K+ channel in oxygen-sensitive pulmonary artery myocytes. EMBO J. 16, 6615.
56. Phartiyal, P., Sale, H., Jones, E.M., Robertson, G.A., 2008. Endoplasmic reticulum retention and rescue by heteromeric assembly regulate human ERG 1a/1b surface channel composition. J. Biol. Chem. 283, 3702.
57. Pinto, L.H., Klumpp, D.J., 1998. Localization of potassium channels in the retina. Prog. Retin. Eye Res. 17, 207.
58. Qu, Y.J., Bondarenko, V.E., Xie, C., Wang, S., Awayda, M.S., Strauss, H.C., Morales, M.J., 2007. W-7 modulates Kv4.3: pore block and Ca2+-calmodulin inhibition. Am. J. Physiol. Heart. Circ. Physiol. 292, H2364.
59. Ravens, U., Wettwer, E., 2011. Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications. Cardiovasc. Res. 89, 776.
60. Refaat, M., Chemaly, E., Lebeche, D., Gwathmey, J.K., Hajjar, R.J., 2008. Ventricular arrhythmias after left ventricular assist device implantation. Pacing Clin. Electrophysiol. 31, 1246.
61. Remillard, C.V., Leblanc, N., 1996. Mechanism of inhibition of delayed rectifier K+ current by 4-aminopyridine in rabbit coronarymyocytes. J. Physiol. 491, 383 (Pt 2).
62. Riendeau, D., Percival, M.D., Brideau, C., Charleson, S., Dube, D., Ethier, D., Falgueyret, J.P., Friesen, R.W., Gordon, R., Greig, G., Guay, J., Mancini, J., Ouellet, M., Wong, E., Xu, L., Boyce, S., Visco, D., Girard, Y., Prasit, P., Zamboni, R., Rodger, I.W., Gresser, M., Ford-Hutchinson, A.W., Young, R.N., Chan, C.C., 2001. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 296, 558.
63. Sanguinetti, M.C., Curran, M.E., Zou, A., Shen, J., Spector, P.S., Atkinson, D.L., Keating, M.T., 1996. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I (Ks) potassium channel. Nature 384, 80.
64. Sanguinetti, M.C., Tristani-Firouzi, M., 2006. hERG potassium channels and cardiac arrhythmia. Nature 440, 463.
65. Scholz, A., Vogel, W., 2000. Tetrodotoxin-resistant action potentials in dorsal root ganglion neurons are blocked by local anesthetics. Pain 89, 47.
66. Schonthal, A.H., 2010. Exploiting cyclooxygenase-(in)dependent properties of COX-2 inhibitors for malignant glioma therapy. Anticancer Agents Med. Chem. 10, 450.
67. Schroeder, B.C., Hechenberger, M., Weinreich, F., Kubisch, C., Jentsch, T.J., 2000. KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J. Biol. Chem. 275, 24089.
68. Scott, C.W., Wilkins, D.E., Trivedi, S., Crankshaw, D.J., 2003. A medium-throughput functional assay of KCNQ2 potassium channels using rubidium efflux and atomic absorption spectrometry. Anal. Biochem. 319, 251.
69. Shapiro, M.S., 2009. An ion channel hypothesis to explain divergent cardiovascular safety of cyclooxygenase-2 inhibitors: the answer to a hotly debated puzzle? Mol. Pharmacol. 76, 942.
70. Singh, G., Triadafilopoulos, G., 1999. Epidemiology of NSAID induced gastrointestinal complications. J. Rheumatol. Suppl. 56, 18.
71. Solomon, S.D., McMurray, J.J., Pfeffer, M.A., Wittes, J., Fowler, R., Finn, P., Anderson, W.F., Zauber, A., Hawk, E., Bertagnolli, M., 2005. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071.
72. Solomon, S.D., Wittes, J., Finn, P.V., Fowler, R., Viner, J., Bertagnolli, M.M., Arber, N., Levin, B., Meinert, C.L., Martin, B., Pater, J.L., Goss, P.E., Lance, P., Obara, S., Chew, E.Y., Kim, J., Arndt, G., Hawk, E., 2008. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117, 2104.
73. Splawski, I., Timothy, K.W., Decher, N., Kumar, P., Sachse, F.B., Beggs, A.H., Sanguinetti, M.C., Keating, M.T., 2005. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc. Nat. Acad. Sci. U.S.A. 102, 8089.
74. Ten Tusscher, K.H., Hren, R., Panfilov, A.V., 2007. Organization of ventricular fibrillation in the human heart. Circ. Res. 100, e87.
75. Trudeau, M.C., Warmke, J.W., Ganetzky, B., Robertson, G.A., 1995. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269, 92.
76. Van Wagoner, D.R., Pond, A.L., McCarthy, P.M., Trimmer, J.S., Nerbonne, J.M., 1997. Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ. Res. 80, 772.
77. Vanegas, H., Schaible, H.G., 2001. Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord. Prog. Neurobiol. 64, 327.
78. Walker, M.C., Kurumbail, R.G., Kiefer, J.R., Moreland, K.T., Koboldt, C.M., Isakson, P.C., Seibert, K., Gierse, J.K., 2001. A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem. J. 357, 709.
79. Wang, Q., Curran, M.E., Splawski, I., Burn, T.C., Millholland, J.M., VanRaay, T.J., Shen, J., Timothy, K.W., Vincent, G.M., de Jager, T., Schwartz, P.J., Toubin, J.A., Moss, A.J., Atkinson, D.L., Landes, G.M., Connors, T.D., Keating, M.T., 1996. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat. Genet. 12, 17.
80. Wang, Q., Shen, J., Splawski, I., Atkinson, D., Li, Z., Robinson, J.L., Moss, A.J., Towbin, J. A., Keating, M.T., 1995. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 80, 805.
81. Wang, S., Morales, M.J., Qu, Y.J., Bett, G.C., Strauss, H.C., Rasmusson, R.L., 2003. Kv1.4 channel block by quinidine: evidence for a drug-induced allosteric effect. J. Physiol. 546, 387.
82. Wang, W., Hino, N., Yamasaki, H., Aoki, T., Ochi, R., 2002. KV2.1 K+ channels underlie major voltage-gated K+ outward current in H9c2 myoblasts. Jpn. J. Physiol. 52, 507.
83. Wareing, M., Bai, X., Seghier, F., Turner, C.M., Greenwood, S.L., Baker, P.N., Taggart, M.J., Fyfe, G.K., 2006. Expression and function of potassium channels in the human placental vasculature. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291, R437.
84. Weber, A., Casini, A., Heine, A., Kuhn, D., Supuran, C.T., Scozzafava, A., Klebe, G., 2004. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J. Med. Chem. 47, 550.
85. Wood, J.N., Baker, M., 2001. Voltage-gated sodium channels. Curr. Opin. Pharmacol. 1, 17.
86. Wuttke, T.V., Seebohm, G., Bail, S., Maljevic, S., Lerche, H., 2005. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol. Pharmacol. 67, 1009.
87. Yan, L., Figueroa, D.J., Austin, C.P., Liu, Y., Bugianesi, R.M., Slaughter, R.S., Kaczorowski, G.J., Kohler, M.G., 2004. Expression of voltage-gated potassium channels in human and rhesus pancreatic islets. Diabetes 53, 597.
88. Yang, W.P., Levesque, P.C., Little, W.A., Conder, M.L., Shalaby, F.Y., Blanar, M.A., 1997. KvLQT1, a voltage-gated potassium channel responsible for human cardiac arrhythmias. Proc. Nat. Acad. Sci. U.S.A. 94, 4017.
89. Zhang, Y., Tao, J., Huang, H., Ding, G., Cheng, Y., Sun, W., 2007. Effects of celecoxib on voltage-gated calcium channel currents in rat pheochromocytoma (PC12) cells. Pharmacol. Res. 56, 267.